Vimentin expression status is a potential biomarker for brain metastasis development in EGFR-mutant NSCLC patients.

ABSTRACT:

Background

Despite advances in systemic therapy and improvements in survival for advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), brain metastasis (BM) remains a poor outcome. Previous studies on risk factors for BM occurrence included unselected patients and biomarker prediction of BM in these populations were not well studied. We aimed to identify the role of epithelial mesenchymal transition (EMT) marker and clinical factors predicting BM in.

Egfr

mutant NSCLC patients.

Methods

Advanced EGFR-mutant NSCLC patients in the King Chulalongkorn Memorial Hospital from January 2013 to December 2017 were included. Vimentin expression was assessed by immunohistochemistry. The correlation between vimentin expression and

SUBMITTER: Teocharoen R 

PROVIDER: S-EPMC7947392 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature